- $304.51m
- $478.50m
- $114.20m
Brief: France Authorizes Reimbursed Compassionate Use of Agenus’ BOT/BAL for MSS Metastatic Colorectal Cancer
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Inc expected to post earnings of $1.35 a share - Earnings Preview
Brief: Agenus To Provide Corporate Update And Second Quarter 2025 Financial Report
Brief: Agenus Inc - Signs Partnership Agreements With Zydus Lifesciences
U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global
U.S. STOCKS ON THE MOVE-Intel, Guardant Health, CrowdStrike
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Microstrategy, FedEx
Agenus jumps on cancer drug partnership with India's Zydus
Brief: Agenus and Zydus Lifesciences Enter $141 Mln Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
Agenus Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Renowned Gi Oncology Leader Dr. Richard Goldberg Joins Agenus As Chief Development Officer
Agenus Inc expected to post a loss of $1.65 a share - Earnings Preview
Brief: Agenus To Provide Corporate Update And First Quarter 2025 Financial Report
Agenus Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Agenus to lower annual burn to about $50 mln by mid-2025
Agenus Inc expected to post a loss of $2.54 a share - Earnings Preview
Brief: Agenus Inc - Incyte To Terminate Agreement With Agenus Effective February 2026
Brief: Agenus Announces Strategic Realignment To Focus On Core Programs And Significantly Reduce Costs